1[1]Edelberg J,Pizzo SV.Lipoprotein(α)regulates plasmin generation and inhibition.Chem Phys Lipids,1994,67:363-368.
2[2]Lacoste L,Lam JYT.Comparative effect of pravastatin and imvastatin on platelet-thrombus formation in hypercholesterolemic coronary patients.JACC,1996,27(suppl):413A.
3[3]Davidson M,MeKenney J,Stein E,et al.Comparison of one year efficacy and safety of atorvastain versus lovastatin in primary hypercholesterlemia.Am J Cardiol,1997,79:1475.
4[4]Hunninghake DB,Stein EA,Mellies MJ.Effects of one year of treatment with provastatin,an HMG-CoA reductase inhibitor,on lipoproteins.J Clin Pharmacol,1993,33:574.
5[5]Edwards CJ,Hart DJ,Spector TD.Oral statins andincreased bone-mineral density in postmenopausal womena.Lancet,2000,355:2218-2219.
6[6]Kirsch T,Nickel J,Sebald W.BMP-2 antagonists emerge from alterations in the low-affinity binding epitope for receptor BMPR-Ⅱ.Embo-J,2000,19:3314-3324.
7[7]Mundy G,Garrett R,Harris S,et al.Stimulation of bone formation in vitro and in rodents by statins.Science,1999,286:1946-1949.
8[8]Mundy G,Garrett R,Harris S,et al.Stimulation of bone formation in vitro and in rodents by statins.Science,2000,285:1946-1949.
9[9]Traianedes K,Dallas MR,Garrett IR,et al.5-Lipoxygenase metabolites inhibit bone formation in vitro.Endocrinology,1998,139:3178-3184.
10[10]Chan KA,Andrade SE,Boles M,et al.Inhibitors of hydroxymethylgutarylcoenzyme A reductase and risk of fracture among older women.Lancet,2000,355:2185-2188.
